Clinical Trial Update: Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of BBT-176 in advanced non-small cell lung cancer after progression on EGFR inhibitors has been terminated; results were posted on 2025-06-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BBT-176

Snippet

Sponsor: Bridge Biotherapeutics, Inc. | Conditions: NSCLC | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-06-06